LEAMINGTON, Ontario — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, has expanded its medical cannabis offering and launched the first EU GMP medical cannabis oil products in Malta. Tilray’s EU-GMP medical cannabis products are now available in pharmacies across Malta, providing patients with safe and reliable access to high-quality medical cannabis.
Related: Tilray Launches Medical Cannabis Products in Malta
Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International Business, said, “Demand for medical cannabis in Malta is growing rapidly and we are incredibly proud to service patients with the high-quality medical cannabis products they rely on and in the formats they prefer.”
In Malta, patients may obtain prescriptions for medical cannabis and a medical cannabis card through family doctors. Medical cannabis cards are issued by Malta’s Superintendent of Public Health.
Tilray has a pioneering track record as a company committed to making EU GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need around the world and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Canada, Tilray Medical Australia, Tilray Medical Australia-New Zealand, Tilray Medical Europe
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including via Tilray Medical. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
- Minority Cannabis Academy: Social Equity in Practice
The Minority Cannabis Academy graduated its first class of 25 students in September. The Academy’s goal is to take advantage of the social equity atmosphere in New Jersey to help those most harmed by prohibition. - Marijuana Policy Project Releases Voter Guide to 2022 Governors’ Races and Cannabis Policy Reform Ahead of Midterm Election
On Tuesday, the Marijuana Policy Project (MPP) released their voter guide to 2022 governors’ races and cannabis policy reform. In 36 states, voters will be choosing their next governor on Election Day. - Green Thumb to Launch “RISE Express” Dispensaries in Florida
Green Thumb Industries Inc., a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced plans to expand its medical retail footprint in Florida through a lease agreement with Circle K, the global convenience store retailer. - Missouri AFL-CIO endorses cannabis legalization constitutional amendment
Missouri AFL-CIO president Jake Hummel on Thursday announced his organization was endorsing the proposal, which will appear on the Nov. 8 ballot as Amendment 3, calling it a “huge step forward for criminal justice reform in Missouri.” - Minnesota’s Black cannabis users far more likely to face arrest than white ones
Black Minnesotans are nearly five times as likely to be arrested on marijuana charges as white ones, according to the latest data from the Bureau of Criminal Apprehension. It’s a disparity that has persisted for years, despite data showing that Black and white residents use cannabis at similar rates. - Lawmakers ask MO governor to add cannabis legalization in special session
A bipartisan group of lawmakers and activists are calling for Missouri Gov. Mike Parson to include marijuana legalization on the agenda of the legislature’s upcoming special session. - In Brief: Pa. Governor Accepting Cannabis Pardon Requests in Sept.
Pennsylvania Gov. Tom Wolf and Lt. Gov. John Fetterman announce the PA Marijuana Pardon Program, offering expedited pardon reviews to people convicted of only minor cannabis possession for personal use. - Michigan State Police stops cannabis testing after false positives
Michigan State Police have acknowledged that its blood tests for marijuana are producing false positives for THC, and it will immediately halt testing. - Missouri Dems expect boost from cannabis, but split on specifics
Support for legalization and heartburn about the amendment’s details have led to soul-searching among Democratic Party officials across the state. The consternation is particularly acute among Black Democratic leaders. - Signatures on Nebraska medical cannabis petitions to get another look
The Nebraska Secretary of State’s Office has agreed to take another look at signatures submitted by a group seeking legalization of medical marijuana to determine if they should have been counted.